gemcitabine

Type: Keyphrase

Name: gemcitabine

First reported 44 mins ago - Updated 44 mins ago - 1 reports

Merrimack announces encouraging results from Phase I solid tumor study

Merrimack Pharmaceuticals, Inc., a biopharmaceutical company, has announced results from a Phase I clinical study that indicate the novel antibody MM-121 can be combined with standard doses of certain cytotoxic agents for investigation as treatment for ... [Published Individual.com - 44 mins ago]

Entities: cytotoxic, carboplatin, solid tumor

First reported Jun 19 2013 - Updated Jun 19 2013 - 1 reports

ATR Inhibition Broadly Sensitizes Ovarian Cancer Cells to Chemotherapy Independent of BRCA Status

Replication stress and DNA damage activate the ATR-Chk1 checkpoint signaling pathway that licenses repair and cell survival processes. In this study, we examined the respective roles of the ATR and Chk1 kinases in ovarian cancer cells using genetic and ... [Published Bionity.com - Jun 19 2013]

Entities: Ovarian Cancer, topotecan, Chemotherapy

First reported Jun 18 2013 - Updated Jun 18 2013 - 4 reports

UPDATE: Silence Therapeutics cancer drug successfully negotiates safety hurdle first time

--adds broker comments, share price--Silence Therapeutics ( LON:SLN ) has successfully negotiated the initial safety assessment of its cancer drug Atu027.It is being used in combination with gemcitabine, the most common chemotherapy, to treat pancreatic ... [Published Proactive Investors.co.uk - Jun 18 2013]

Entities: Silence Therapeutics Plc, antineoplastic, Pancreatic Cancer, Toxicity

First reported Jun 04 2013 - Updated Jun 05 2013 - 4 reports

Company at Centre of Chemo Drugs Scare Charged less than Previous Supplier

There's a shocking new twist in the province's diluted cancer drugs scandal.The legislative committee looking into the situation has learned Marchese Hospital Solutions was selling drug mixtures for far less money than the previous supplier.The New Democrats ... [Published AM980 CFPL - Jun 05 2013]

Entities: Drugs, Patient, cyclophosphamide, gemcitabine

First reported Jun 04 2013 - Updated Jun 04 2013 - 2 reports

Merrimack Pharmaceuticals Inc

Merrimack Pharmaceuticals Phase 1 Research Supports MM-121 Potential

Merrimack Pharmaceuticals' Phase 1 Research Supports MM-121 Potential For Investigation As Combination With Chemotherapy In Patients With Advanced Solid Tumors Results Presented at ASCO 2013 Establish the Safety Profile of MM-121 and Show Preliminary ... [Published Big News Network - Jun 04 2013]

Entities: Merrimack Pharmaceuticals Inc, Phase I, Cabazitaxel, Pemetrexed

First reported Jun 04 2013 - Updated Jun 04 2013 - 3 reports

Celgene Corporation

Celgene Stock Still Has Plenty Of Room To Grow Due To A Strong Product Line

Celgene Stock Still Has Plenty of Room to Grow Due to a Strong Product LineThe global biopharmaceutical company, Celgene (CELG), has had quite a run this year, and judging by its sales and pipeline of products, the stock should continue to see positive ... [Published Seeking Alpha - Jun 04 2013]

Entities: Celgene Corporation, Pancreatic Cancer, Abraxane, Psoriatic Arthritis

First reported Jun 03 2013 - Updated Jun 04 2013 - 3 reports

Sanofi SA

Sanofi to discontinue phase III studies of iniparib & otamixaban as drugs fail to meet endpoints

Sanofi has provided an update on topline results of two phase III clinical studies of its investigational compounds iniparib and otamixaban respectively.The randomized phase III ECLIPSE trial of iniparib in squamous non-small cell lung cancer (Sq NSCLC) ... [Published PharmaBiz - Jun 04 2013]

Entities: Iniparib, Otamixaban, Phase III, Sanofi SA

First reported Jun 03 2013 - Updated Jun 03 2013 - 2 reports

Analyses of MPACT Trial Evaluating ABRAXANE® Combination Therapy for the Treatment of Advanced Pancreatic Cancer Presented at ASCO 2013

Home » Press Releases » Data Suggest Treatment with ABRAXANE plus Gemcitabine Reduces Levels of CA19-9 and Increases the Frequency of PET Responses; Both Tools Found to be Potential Prognostic Factors of Overall SurvivalCelgene International Sàrl, a subsidiary ... [Published BioPortfolio - Jun 03 2013]

Entities: Abraxane, gemcitabine, Patient, Pancreatic Cancer

First reported Jun 03 2013 - Updated Jun 03 2013 - 2 reports

Peregrine Pharma (PPHM) Moves Higher on Positve ASCO Data

Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM) reported today that data was presented at the 2013 ASCO Annual Meeting from two clinical trials evaluating the company's lead clinical candidate bavituximab. In the first study presented, interim data from ... [Published Street Insider - Jun 03 2013]

Entities: Bavituximab, gemcitabine, Peregrine Pharmaceuticals Inc

First reported Jun 03 2013 - Updated Jun 03 2013 - 3 reports

Halozyme Therapeutics Inc Announces Phase 1b Clinical Trial Of PEGPH20

Halozyme Therapeutics Inc announced results from a Phase 1b trial of PEGPH20 (PEGylated Recombinant Human Hyaluronidase), an investigational new biologic, in combination with gemcitabine for the treatment of patients with stage IV metastatic pancreatic ... [Published Reuters - Jun 03 2013]

Entities: Halozyme Therapeutics Incorporated, gemcitabine, Clinical trials

First reported May 23 2013 - Updated May 24 2013 - 8 reports

Celgene sNDA of Abraxane obtains FDA priority review status

Celgene International has obtained FDA priority review status for Abraxane (paclitaxel protein-bound particles for injectable suspension) supplemental new drug application (sNDA).The application covers the use of Abraxane and gemcitabine combination therapy ... [Published Pharmaceutical Business Review - May 24 2013]

Entities: Abraxane, Celgene Corporation, Pancreatic Cancer, gemcitabine, Metastatic

First reported May 23 2013 - Updated May 23 2013 - 2 reports

OncoGenex plans to initiate OGX-42 Phase 2 trial in patients with advanced squamous cell lung cancer

OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) today announced plans for the initiation of the Cedar™ clinical trial, an investigator-sponsored, randomized, open-label Phase 2 trial evaluating OGX-427 in previously untreated patients with advanced squamous ... [Published News-Medical.Net - May 23 2013]

Entities: OncoGenex Pharmaceuticals, squamous cell, OGX-427

Quotes

...with these chemotherapy agents in certain tumor types," said Akos Czibere, MD, PhD, Senior Medical Director of the MM-121 program at Merrimack. "MM-121 has the potential to complement the impact of several existing standard-of-care therapies and we look forward to further exploring its promise."

Merrimack announces encouraging results from Phase I solid tumor study [Published Individual.com - 44 mins ago]

"Taken together, we believe the data from these trials demonstrate the significant potential of indoximod and its action as an IDO pathway inhibitor to disrupt the mechanisms by which cancer evades a patient's immune system and to boost the effect of other therapies, including cytotoxic agents and cancer vaccines for the treatment of solid tumors" commented Charles J Link, Jr., MD, Chairman and CEO of NewLink Genetics

NewLink announces encouraging results from Phase I solid tumor studies [Published Individual.com - 45 mins ago]

"With export production a key goal for GKP in the near term, the political instability shows little sign of subsiding. Nevertheless, GKP continues to deliver strong operational results, with further oil discoveries and increasing production rates from Shaikan."

Broker spotlight II including Medusa Mining, Herencia Resources, Silence Therapeutics, Frontier M ... [Published Proactiveinvestors United Kingdom website - Jun 18 2013]

Professor Joachim Drevs, the chair of the DSMB, said: "The study protocol calls for the safety cohort to expand from three to six if any of the three subjects experiences an unacceptable toxicity; we did not find this necessary. We look forward to seeing Atu027 progress in the main part of the study."

Silence Therapeutics cancer drug successfully negotiates safety hurdle first time [Published Proactive Investors.co.uk - Jun 18 2013]

More Content

sort by: Date \| Relevance
Merrimack announces encouraging results from Ph... [Published Individual.com - 44 mins ago]
NewLink announces encouraging results from Phas... [Published Individual.com - 45 mins ago]
The Overlooked Potential Value of the Nuvilex T... [Published I Stock Analyst - 23 hours ago]
UPDATE: Silence Therapeutics cancer drug succes... [Published Proactive Investors USA - Jun 19 2013]
ATR Inhibition Broadly Sensitizes Ovarian Cance... [Published Bionity.com - Jun 19 2013]
Cucurmosin Kills Human Pancreatic Cancer SW-199... [Published Bionity.com - Jun 19 2013]
Proactive news summary: Tethys Petroleum, Medus... [Published Proactiveinvestors United Kingdom website - Jun 18 2013]
Proactive news summary: Tethys Petroleum, Medus... [Published Proactiveinvestors United Kingdom RSS feed - Jun 18 2013]
Broker spotlight II including Medusa Mining, He... [Published Proactiveinvestors United Kingdom website - Jun 18 2013]
Broker spotlight II including Medusa Mining, Si... [Published Proactiveinvestors United Kingdom RSS feed - Jun 18 2013]
UPDATE: Silence Therapeutics cancer drug succes... [Published Proactive Investors.co.uk - Jun 18 2013]
Silence Therapeutics progresses Atu027 to Phase... [Published Stock Market Wire - Jun 18 2013]
Silence Therapeutics Plc Updates On Progressing... [Published Reuters - Jun 18 2013]
Silence Therapeutics cancer drug successfully n... [Published Proactive Investors.co.uk - Jun 18 2013]
Silence Therapeutics : Atu027 update: progressi... [Published Investegate - Jun 18 2013]
GTX Inc.: The Company's Next Moves [Published Seeking Alpha - Jun 17 2013]
SARCOMAS in veterans exposed to Agent Orange an... [Published Examiner.com - Jun 15 2013]
Threshold Pharmaceuticals, Inc. (THLD): A Biote... [Published InsiderMonkey.com - Jun 14 2013]
Threshold Pharmaceuticals: A Biotech That Inves... [Published Motley Fool - Jun 14 2013]
Anti-Cancer Agent ?Tarceva$,? Obtained Approval... [Published Noodls - Jun 14 2013]
Near A 52-Week Low, Is OncoGenex Pharmaceutical... [Published Seeking Alpha - Jun 13 2013]
NICE knocks back Lilly’s Alimta in new setting [Published PMLive - Jun 13 2013]
Chemoimmunotherapy, chemoradiotherapy add no su... [Published Oncology Report - Jun 13 2013]
Sanofi's two Phase III cancer and ACS studies f... [Published Individual.com - Jun 12 2013]
Peregrine reports encouraging data from breast ... [Published Individual.com - Jun 12 2013]
Halozyme announces encouraging results from Pha... [Published Individual.com - Jun 12 2013]
Celgene announces encouraging data from Phase I... [Published Individual.com - Jun 12 2013]
Nuvilex Forecasts Cell Encapsulation's Role in ... [Published Individual.com - Jun 12 2013]
Comment on The efficacy and toxicity of gemcita... [Published BioPortfolio - Jun 12 2013]
New Market Research Report: Pfizer Inc. - Produ... [Published Live-PR.com - Jun 11 2013]

Blogs

sort by: Date \| Relevance
Proactive news summary: Tethys Petroleum, Medus... [Published Proactiveinvestors United Kingdom website - Jun 18 2013] Not many companies can boast that their shares have more than doubled in the past six months. But that is the case for Tethys Petroleum ( LON:TPL , TSE:TPL), which confirmed a farm-out deal with French major Total and the China National Petroleum ...
Broker spotlight II including Medusa Mining, He... [Published Proactiveinvestors United Kingdom website - Jun 18 2013] Veteran mining analyst John Meyer, at broker SP Angel, shines a spotlight on Philippines-focused gold miner Medusa Mining ( LON:MML ) and sees no reason for the firm's share price fall. Shares have dropped from 300p at the end of March to 111p today ...
4 Healthcare Stock Stories Attracting Attention... [Published Wall St. Cheat Sheet - Jun 05 2013] StemCells ( NASDAQ:STEM ): Closing price $ 1.86StemCells has reached an arrangement with the institutional investor Lincoln Park Capital Fund, through which it has the right to sell as much as $30 million of common stock to Lincoln Park. Proceeds will ...
4 Healthcare Stock Stories Attracting Attention... [Published Wall St. Cheat Sheet - Jun 05 2013] StemCells ( NASDAQ:STEM ): Closing price $1.86 StemCells has reached an arrangement with the institutional investor Lincoln Park Capital Fund, through which it has the right to sell as much as $30 million of common stock to Lincoln Park. Proceeds ...
Silence Therapeutics looks forward to critical ... [Published Proactiveinvestors United Kingdom website - May 29 2013] The coming year will be critical for Silence Therapeutics ' ( LON:SLN ) transition into a drug development company, its chief executive said today. The group specialises in gene silencing, a technology that encourages faulty genes to switch themselves ...

Press Releases

sort by: Date \| Relevance
Samenvatting: Op ASCO 2013 is analyse van MPACT... [Published Business Wire Health News - Jun 04 2013]
Présentation des analyses de l'essai MPACT éval... [Published Business Wire Health News - Jun 04 2013]
Analyses of MPACT Trial Evaluating ABRAXANE® Co... [Published Business Wire Health News - Jun 03 2013]
Halozyme's Phase 1b Clinical Trial Of PEGPH20 W... [Published PR Newswire: Health - Jun 03 2013]
Superiority of afatinib* over comparator chemot... [Published Business Wire Health News - Jun 01 2013]